Understanding APC

/Understanding APC

Cognition and Hormone Therapy (ADT)

There have been numerous studies examining the how hormone deprivation (ADT), in the treatment of prostate cancer, has on a man’s cognition. There have been contradictor studies about this issue, however having had the experience and the honor of dealing with so many men with prostate cancer treated with androgen deprivation therapy (ADT), as well [...]

A Prospective Evaluation Of The Health Related Quality of Life In Men Receiving Primary and Secondary Treatment for Prostate Cancer

Men with both high risk and intermediate risk prostate cancer will receive primary treatment and many also receive a second line of treatment. In a study that was designed to assess the impact of receiving both first and second line treatment on a man’s Health Related Quality of Life (HRQoL), researchers determined that men who [...]

Understanding the Reality of the Side Effects from Early Chemotherapy

Ever since the research showing that men who are newly diagnosed with very aggressive prostate cancer have a significant life extension advantage if they move immediately to chemotherapy (with docetaxel) along with hormone therapy (ADT) there has been, what I can only describe as a paradigm shift in the clinical care of men with metastatic [...]

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]

What is the Actual Clinical Benefit of Using Low Dose Prednisone Along with Prostate Cancer Chemotherapy with Docetaxel?

Randomized trials have clearly demonstrated that when low dose Prednisone (P) is combined with docetaxel chemotherapy (D) to treat prostate cancer there is a survival benefit. What is the role of the prednisone and does it actually provide any additional benefit to the docetaxel treatment itself? To answer this question a retrospective study was performed [...]

How Quickly You Might Die From Advanced Prostate Cancer Depends On What Organs Are Involved

Researchers at the Duke Cancer Institute along with other cancer centers, in the largest analysis of its kind have found that the organ site where prostate cancer spreads has a direct impact on a man’s survival. They found that men with lymph-only metastasis statistically have the longest overall survival possibility, while those with liver involvement [...]

The Really Big Question We all Ask, Will I Die from Prostate Cancer?

Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer  in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%.  Despite this very significant drop in late stage diagnoses prostate cancer is [...]

Adjuvant Radiotherapy Benefits Survival in Subsets of Men With Node-Positive Prostate Cancer

In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy)  enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]

Long-Term Survival Possible in Prostate Cancer With Bone Metastases

Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]

Enzalutamide (Xtandi) Improves The Quality of Life As Well As Extending Life In Men With Castrate Resistant Prostate Cancer

In clinical trials Enzalutamide (Xtandi) significantly increased the overall survival and radiographic progression-free survival of men when compared with placebo. The trial, called PREVAIL evaluated men who were asymptomatic and minimally symptomatic, chemotherapy-naive with metastatic castration-resistant prostate cancer. The researchers expanded the data analysis and evaluated the effect of Xtandi on the men’s health-related quality [...]